Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1990-09-07
1993-03-16
Nucker, Christine M.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303911, 5303913, 5303917, 5303919, 424 11, 424 9, 424 8591, C07K 1528, C07K 1706, A61K 4902
Patent
active
051945940
ABSTRACT:
Modified antibodies are disclosed which have been modified by chemical conjugation with a heterobifunctional reagent, such as SPDP. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in such diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4698320 (1987-10-01), Urnmovitz
patent: 4724213 (1988-02-01), Epstein
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 5011676 (1991-04-01), Thakun
patent: 5019393 (1991-05-01), Ito et al.
patent: 5043340 (1991-08-01), Cullinan
Colcher et al., (1981) PNAS 78(5): 3199-3203.
Pelham et al., (1983) Cancer Immunol Immunotha 15:210-216.
Srinivasachar et al., (1989) Biochemistry 28(6) 2501-2509.
Blair (1983) J. Immunol. Methods 59:129-143.
Jung et al., (1981) Biochem. Biophys Res. Commun. 101(2): 599-606.
Lin et al, (1985) PNAS USA 82:8648-8652.
Wawrzynczak et al., (1987) in Immununconyate Antibody Coyngates in Radioniginet Therapy of Cancer, CW Vogeled NY Oxford Univ. Press pp. 28-55.
"Macromolecular Photoaffinity Labeling with Radioactive Photoactivable Heterobifunctional Reagents", by Tae H. Ji, et al., Analytical Bioch. 121:286-289 (1982).
"Addition of Sulfhydryl Groups to Escherichia coli Ribosomes by Protein Modification with 2-Iminothiolane", by Rodney Jue, et al., Bioch. 17:5399-5405 (1978).
"Photoactivated Heterobifunctional Cross-Linking Reagents Which Demonstrate the Aggregation State of Phospholipase A2", by Randolph V. Lewis, et al., Bioch. 16:5650-5654 (1977).
"Synthesis and Application of Cleavable Photoactivable Heterobifunctional Reagents", by Elio F. Vannin, et al., Biochemistry 20:6754-6760 (1981).
"Localization of Mammary Tumors in Vivo with 1-Labeled FAb Frangments of Antibodies Against Mouse Mammary Epithelial (MME) Antigens", by T. Wilbanks, et al., Cancer 48:1768-1775 (1981).
"Biological Response Modifiers: The New Immunotherapy", by Kenneth A. Foon, Cancer Res. 49:1621-1639 (1989).
"Improved Radioimaging and Tumor Localization with Monoclonal F(ab')2" by Richard L. Wahl, et al., J. Nucl. Med." 24:316-325 (1983).
"Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4", by U. K. Laemmli, Nature 227:680-685 (1970).
"Two New Monoclonal Antibodies, Lym-1 and Lym-2, Ractive with Human B-Lymphocytes and Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential", by Alan L. Epstein, et al., Cancer Res. 47:830-840 (1987).
"Determination of Sulfhydryl Groups with 2,2'-or 4,4'-Dithiodipyridine", by D. R. Grassetti, et al., Arch. Bioch. Biophys. 119:41-49 (1967).
"Protein Thiolation and Reversible Protein-Protein Conjugation", by Jan Carlsson, et al., Biochem. J. 173:723-737 (1978).
"On the Fragmentation of Monoclonal 1gG1, 1gG2a, and 1gG2a, and 1gG2b from BALB/c MICE", by Peter Parham J. Immuno 131:2895-2902 (1983).
"I Radiolabeling of Monoclonal Antibodies for In Vivo Procedures", by Stanley L. Mills, et al., Hybridoma 5:265-275 (1986).
Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridly Disulphide Groups, Hybridoma 5:1-8 (1986).
National Library of Medicine, Database Medline, accession no. 89048210, Brown BA: "Conjugation of metallothionein to a murine monoclonal antibody", Anal Biochem. 1988 Jul.:172(1): 22-8.
Cancer Research, vol. 47, 1987, P. E. Thorpe et al.: "New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo", see p. 5924-p. 5931, p. 5927, Results and p. 5929-30.
Cancer Immunol Immunother, vol. 31, 1990, M. A. Winkler et al.: "Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody-cross-linked to OKT3", see pp. 278-284, p. 282-283.
Biochemistry, vol. 17, No. 8, 1978, Te Piao King et al.: "Preparation of protein conjugates via intermolecular disulfide bond formation", see page 1499-p. 1506, p. 1505.
The Journal of Immunology, vol. 141, No. 10, 1988, M. J. Glennie et al.: "Bispecific F(AB'y)2 antibody for the delivery of saporin in the treatment of lymphoma", see pp. 3662-3670; p. 3665, left column first paragraph and p. 3663, right column.
National Library of Medicine, Database Medline, NLM accession No. 88060540, Koizumi M: "Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate". An improved method:, J. Immunol. Methods 1987 Nov. 23; 104(1-2); 93-102.
Epstein Alan L.
Khawli Leslie A.
Kim Kay K.
Nucker Christine M.
Techniclone Inc.
LandOfFree
Modified antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-351611